bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Update

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a significant decline in short interest in October. As of October 15th, there was short interest totaling 192,300 shares, a decline of 76.2% from the September 30th total of 807,500 shares. Currently, 4.5% of the company’s stock are short sold. Based on an average trading volume of 2,760,000 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 2,760,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 4.5% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Wall Street Zen downgraded shares of bioAffinity Technologies to a “strong sell” rating in a report on Saturday, September 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce”.

bioAffinity Technologies Price Performance

Shares of NASDAQ:BIAF opened at $2.48 on Thursday. The company has a market capitalization of $11.16 million, a P/E ratio of -0.12 and a beta of 2.32. The company’s 50-day moving average is $4.94 and its 200 day moving average is $7.91. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.63 and a current ratio of 0.64. bioAffinity Technologies has a fifty-two week low of $2.34 and a fifty-two week high of $46.53.

bioAffinity Technologies (NASDAQ:BIAF) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($3.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.00) by ($0.90). bioAffinity Technologies had a negative return on equity of 845.68% and a negative net margin of 152.16%.The company had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.51 million.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.